Skip to content
Screener

ADMA Biologics ADMA Total Liabilities & Equity

Total Liabilities & Equity at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$1.31B-6.7%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
$229.5M
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$329.68M-21.9%
Absci Corporation logo
Absci CorporationABSI
$195.59M-15.9%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$490.78M+288%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$1.29B+81.1%

Other financials

Income statement

See full
Revenue$124.4M+2.0%
Gross profit$86.3M+28.3%
Operating income$52.4M+22.5%
Net income$37.8M+10.5%
EPS (diluted)$0.16+14.3%

Balance sheet

See full
Cash & equivalents$136.0M+50.7%
Total debt$203.9M+1,855%
Total equity$408.2M+2.5%
Total assets$684.2M+22.5%

Cash flow

See full
Operating cash flow$29.5M+39.7%
CapEx$2.3M-6.9%
Free cash flow$27.3M+45.8%

Valuation

See full
Market cap$2.25B-49.1%
Enterprise value$2.32B-46.6%
P/E13.3×-7.9×
P/S4.4×-4.9×

Profitability

See full
Gross margin64.7%+11.7pp
Operating margin43.8%+11.0pp
Net margin33%-11.1pp
FCF margin22.7%+8.9pp

Returns & leverage

See full
Return on equity41.9%-29.3pp
Debt / equity0.5×+0.5×
Current ratio+1.6×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:16 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001140361-26-031445
Line itemJune 30, 2026December 31, 2025
STOCKHOLDERS' EQUITY
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding--
Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized,June 30, 2026: 241,089,992 issued and 225,355,228 outstanding;December 31, 2025: 239,793,566 issued and 237,874,496 outstanding2424
Treasury stock, at cost, 15,734,764 and 1,919,070 shares as of June 30, 2026 and December 31, 2025, respectively(188,452)(32,090)
Additional paid-in capital675,139671,039
Accumulated deficit(78,503)(161,653)
TOTAL STOCKHOLDERS' EQUITY408,208477,320
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$$684,210624,242

Item 1. Financial Statements.

FAQ

What is ADMA Biologics's total liabilities & equity?
ADMA Biologics (ADMA) reported total liabilities & equity of $684.21M in Q2 2026.
How has ADMA Biologics's total liabilities & equity changed year-over-year?
ADMA Biologics's total liabilities & equity increased by 22.5% year-over-year, from $558.38M to $684.21M.
What is the long-term trend for ADMA Biologics's total liabilities & equity?
Over 5 years (2020 to 2025), ADMA Biologics's total liabilities & equity has grown at a 24.6% compound annual growth rate (CAGR), from $207.67M to $624.24M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about ADMA Biologics's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude